CMH — Chordate Medical Holding AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK16.40m
- SEK13.87m
- SEK0.66m
Annual income statement for Chordate Medical Holding AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.618 | 0.882 | 0.109 | 0.976 | 0.665 |
| Cost of Revenue | |||||
| Gross Profit | 2.51 | 1.93 | 0.034 | 1.31 | 1.99 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 20 | 22.6 | 28.1 | 30.5 | 28.1 |
| Operating Profit | -19.4 | -21.7 | -28 | -29.6 | -27.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -19.8 | -21.8 | -27.9 | -29.2 | -27.3 |
| Net Income After Taxes | -19.8 | -21.8 | -27.9 | -29.2 | -27.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -19.8 | -21.8 | -27.9 | -29.2 | -27.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -19.8 | -21.8 | -27.9 | -29.2 | -27.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -77.1 | -32.9 | -47.8 | -33.9 | -19.9 |
| Dividends per Share |